What Does Tenax Therapeutics, Inc.'s 89.77% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline
Suit alleges Tenax Therapeutics, Inc. failed to disclose key facts to investors from November 13, 2023 through August 7, 2026; lead plaintiff deadline is December 28, 2026
BENSALEM TOWNSHIP, Pa., Nov. 9, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith today reported that a securities class action lawsuit is pending against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) on behalf of investors who acquired its securities from November 13, 2023 through August 7, 2026. The Tenax Therapeutics, Inc. case, Katz v. Tenax Therapeutics, Inc. et al., was filed on October 26, 2026 in the U.S. District Court North Carolina Middle District (Case No. 1:26-cv-01264).
Investors with losses on Tenax Therapeutics, Inc. securities can contact the Law Offices of Howard G. Smith about the Tenax Therapeutics, Inc. lawsuit before the December 28, 2026 lead plaintiff deadline.
Key deadlines and dates for Tenax Therapeutics, Inc. investors
- Lead plaintiff deadline: December 28, 2026
- Class period: November 13, 2023 through August 7, 2026
- Complaint filed: October 26, 2026
What happened?
On August 10, 2026, Tenax issued a press release reporting topline results from its Phase 3 LEVEL clinical trial. The press release stated that TNX-103 "did not meet its primary endpoint of improvement in the 6-minute walk distance versus placebo, or the key secondary endpoint of improvement in Kansas City Cardiomyopathy Questionnaire total symptom score."
On this news, Tenax's stock fell $12.06 per share, or 89.77%, to close at $1.38 per share on August 10, 2026, thereby injuring investors.
What is the Tenax Therapeutics, Inc. lawsuit about?
The Tenax Therapeutics, Inc. securities lawsuit alleges that, between November 13, 2023 and August 7, 2026, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Tenax Therapeutics, Inc.'s business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose that: (1) TNX-103 was less effective than Defendants had led investors to believe; (2) accordingly, TNX-103's overall clinical, regulatory, and commercial prospects were overstated; and (3) as a result, defendants' positive statements about Tenax Therapeutics, Inc.'s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
"The lawsuit against Tenax Therapeutics, Inc. alleges that, among other things, the Company failed to tell investors that TNX-103 was less effective than Defendants had led investors to believe. Tenax Therapeutics, Inc. investors who bought during the class period may be able to pursue their losses, and the December 28, 2026 deadline is where that process begins," said Howard G. Smith of The Law Offices of Howard G. Smith.
Next steps for Tenax Therapeutics, Inc. investors
Tenax Therapeutics, Inc. investors who suffered losses may contact The Law Offices of Howard G. Smith to learn about pursuing their claims.
Lead plaintiff motions in the Tenax Therapeutics, Inc. class action are due to the Court by December 28, 2026. For more information, visit the firm's website, email [email protected], or call (215) 638-4847.
If you purchased Tenax Therapeutics, Inc. securities during the class period, you may retain counsel of your choice, or you may take no action and remain an absent class member. No class has been certified in the Tenax Therapeutics, Inc. case so far.
Common questions from Tenax Therapeutics, Inc. investors
Who is eligible? Investors who acquired Tenax Therapeutics, Inc. securities from November 13, 2023 through August 7, 2026 and suffered losses may qualify for the class in the Tenax Therapeutics, Inc. shareholder lawsuit.
What is the deadline? Lead plaintiff motions in the Tenax Therapeutics, Inc. case are due by December 28, 2026.
Can I recover without being lead plaintiff? Yes, Tenax Therapeutics, Inc. investors may take no action and remain absent class members.
Does it cost anything? The Law Offices of Howard G. Smith works on contingency, meaning Tenax Therapeutics, Inc. investors owe no attorneys' fees out of pocket. Any attorneys' fees and litigation expenses are paid solely from a recovery, if achieved, and require court approval.
About The Law Offices of Howard G. Smith
The Law Offices of Howard G. Smith has helped injured investors recover their money for more than 15 years. The firm prosecutes securities fraud, takeover, and derivative litigation against public companies and their officers, directors, and advisors in federal and state courts nationwide, and has helped clients recover hundreds of millions of dollars in losses. Clients speak directly with a lawyer, who will promptly answer any question.
Prior results do not guarantee a similar outcome.
Related links
- Tenax Therapeutics, Inc. case page, The Law Offices of Howard G. Smith
- Complaint: Katz v. Tenax Therapeutics, Inc. et al., U.S. District Court North Carolina Middle District
- Tenax Press Release
- Tenax Therapeutics, Inc. SEC filings index, EDGAR
- The Law Offices of Howard G. Smith
Contact
The Law Offices of Howard G. Smith
3070 Bristol Pike, Suite 112
Bensalem, PA 19020
Email: [email protected]
Telephone: (215) 638-4847
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
SOURCE Law Offices of Howard G. Smith
Share this article